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Many centers showed that since they started a lung
transplantation program, overall survival improved
every 5- or 10-year cohort. This is also seen in com-
bined international data [1]. Many changes in donor
selection, organ preservation, and perioperative manage-
ment improved short-term survival despite the usage of
extended criteria donors. In parallel, also long-term sur-
vival improved, likely because of gained experience and
better anticipation on developing diseases after trans-
plantation. A current relative standstill in the arsenal of
medication directed on the prevention of (chronic)
transplant dysfunction hampers further survival
improvement. Lung transplant patients still have a
shorter life expectancy than normal, especially caused by
side effects of immunosuppression and our inability to
stop chronic deterioration of the graft. Malignancies are
an emerging cause of death besides the still persistent
chronic lung allograft dysfunction (CLAD).
This, till now inevitable, downside of the success of
lung transplantation is well described in the paper of
Raskin et al. [2] in this issue. This paper focused on
how death cause and death burden changed over the
years in a program with improving results. Intriguing is
that the patients that do die still die after a median per-
iod of 3 years, across all primary diseases. This suggests
that their death is not prevented by current anti-rejec-
tion and infection protocols that have hardly changed
over the years in lung transplantation.
This paper suggests room for improvement and
polishing of treatment protocols, preferentially in the
first postoperative years. Moreover, by virtue of its
descriptive nature, the paper inevitably raises a num-
ber of questions to causes and variables that lead to
mortality in this patient group. The influence of
recipient age and type of immunosuppression is men-
tioned in the discussion, but not extensively
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described. However, in a number of single-center
studies an evident relation between type of immuno-
suppressive drugs and long-term outcomes such as
survival, renal function, and skin cancer, both in
maintenance setting [3,4] or after conversion of drugs
[4], has been described.
For this reason, the current paper justifies further
study in European context, involving medium-to-large
volume centers with state-of-the-art long-term results.
Focus of interest may be:
• Incidence and type of cancer in relation to type and,
particularly, target levels of immunosuppression
• Risk of lung cancer in relation to bilateral vs. unilat-
eral lung transplantation
• Cardiovascular risk in relation to recipient age and
pretransplant vascular condition
• The influence of primary disease on the mode of
death. Especially, the high number of deaths by infec-
tion after transplantation for fibrosis needs brother
analysis.
Raskin et al. [2] show that the balance in protection
and harm by the current used protocols in their pro-
gram is not optimal as it is in all programs. The devia-
tion of the survival curves of the last two 5-year cohorts
in their study might indicate that this improvement has
started. For real improvement, focus of research on pro-
tocols and new drugs should be aimed at preventing
CLAD with less side effects.
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